CTOs on the Move

Aulos Bioscience

www.aulosbio.com

 
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.aulosbio.com
  • 245 main street Floor 12
    Cambridge, MA USA 02142
  • Phone: 617.294.6790

Executives

Name Title Contact Details

Funding

Aulos Bioscience raised $40M on 01/08/2021

Similar Companies

LigoCyte Pharmaceuticals

LigoCyte Pharmaceuticals, Inc is a Bozeman, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Encodia

Encodia is developing an innovative Next-Gen digital proteomics platform to enable democratized protein sequencing. Our goal is to make protein sequencing easy and ubiquitous by using a novel reverse-translation technology that turns peptide sequences into DNA. The DNA can be read by an NGS DNA sequencer, providing a path to breakthrough proteomics research at a scale that is not practical or cost-effective using current technologies.

Kinnos

Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.

VIRxSYS Corporation

VIRxSYS Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ARCA biopharma

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.